Switching From Regimens Consisting of a RTV-Boosted Protease Inhibitor Plus TDF/FTC to a Combination of Raltegravir Plus Nevirapine and Lamivudine in HIV Patients With Suppressed Viremia and Impaired Renal Function (RANIA Study) (Pilot Study) Protocol MK-0518-284-02

Trial Profile

Switching From Regimens Consisting of a RTV-Boosted Protease Inhibitor Plus TDF/FTC to a Combination of Raltegravir Plus Nevirapine and Lamivudine in HIV Patients With Suppressed Viremia and Impaired Renal Function (RANIA Study) (Pilot Study) Protocol MK-0518-284-02

Discontinued
Phase of Trial: Phase II

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs Lamivudine (Primary) ; Nevirapine (Primary) ; Raltegravir (Primary) ; Atazanavir/ritonavir; Darunavir/ritonavir; Emtricitabine/tenofovir disoproxil fumarate; Lopinavir/ritonavir
  • Indications HIV infections
  • Focus Therapeutic Use
  • Acronyms RANIA
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 06 Sep 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Aug 2017.
    • 01 Dec 2015 Planned End Date changed from 1 Jul 2017 to 1 Aug 2017 as reported by ClinicalTrials.gov.
    • 07 Oct 2015 Planned End Date changed from 1 Oct 2017 to 1 Jul 2017, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top